Solventum Corporation SOLV
89.50
0.91
1.03%
as of 25 Sep
- Market cap
- $15.1B
- P/E
- 10.9×
Follow SOLV
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Solventum Corporation (SOLV) Net income
Solventum Corporation's net income for fiscal 2025 was $1.6B, up 224.8% from $479.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.4B. Solventum Corporation ranks 4th of 55 Medical Instruments & Supplies companies by net income.
Net income, annual
Annual
| Period | Net income | Change |
|---|---|---|
| FY2025 | $1.6B | 224.84% |
| FY2024 | $479.0M | (64.41%) |
| FY2023 | $1.3B | 0.22% |
| FY2022 | $1.3B | — |
Quarterly
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $92.0M | 607.69% |
| Mar 2026 | $13.0M | (79.37%) |
| Dec 2025 | $63.0M | (95.02%) |
| Sep 2025 | $1.3B | 1,306.67% |
| 11 more quarters | Free account |
Net income against peers
| Company | Net income |
|---|---|
| SOLV Solventum Corporation | $1.4B |
| ALC Alcon compare | $643.0M |
| COO The Cooper Companies, Inc. compare | $570.3M |
| WST West Pharmaceutical Services, Inc. compare | $564.9M |
| ALGN Align Technology, Inc. compare | $413.6M |
| ATR AptarGroup, Inc. compare | $362.9M |
| RGEN Repligen Corporation compare | $41.5M |
| AVTR Avantor, Inc. compare | −$578.0M |
| BAX Baxter International Inc. compare | −$1.1B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on SOLV
- Revenue
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement